NY-ESO-1 T cells for the treatment of synovial sarcoma

NY-ESO-1 T cells are genetically modified T cells that are re-infused into the patient. It is being developed for the treatment of cancers including melanoma, multiple myeloma and synovial sarcoma. It is currently in Phase III clinical trials.